Zongertinib demonstrates promising efficacy in HER2-mutated NSCLC, with a 69% PFS rate and 73% duration of response over 6 months. The investigational TKI shows a favorable toxicity profile, with ...
Researchers have discovered how a common mutation in a high-risk leukemia subtype drives the cancer's aggressiveness and have identified drugs that may work with existing precision medicines to ...
US regulators’ use of a speedy clearance pathway for a new frontline indication for asciminib for chronic myeloid leukemia (CML) has raised questions due to the number of medications already available ...
Afatinib versus chemotherapy in advanced NSCLC with uncommon EGFR mutations: A pooled individual patient–level survival analysis of ACHILLES/TORG1834 and LUX-Lung 2/3/6. Lorlatinib as first-line ...
When it comes to selecting a cost-effective, first-line tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia (CML), consider the treatment goal. For survival, generic imatinib ...
The U.S. Food and Drug Administration has approved Augtyro (repotrectinib), a next-generation tyrosine kinase inhibitor (TKI), for the treatment of patients with neurotrophic tyrosine receptor kinase ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Augtyro™ (repotrectinib) for ...
Genitourinary oncologists discuss the safety and efficacy of IO/TKI and IO/IO combination therapies in advanced renal cell carcinoma. Tian Zhang, M.D., M.H.S.: In terms of front-line therapies, as we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results